Clinical Trial Update: Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating LAM-002A in C9orf72-associated amyotrophic lateral sclerosis has completed, assessing safety, tolerability, and biological activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• C9orf72-associated Amyotrophic Lateral Sclerosis

Drugs mentioned

• LAM-002A (LAM-002A)

Snippet

Sponsor: OrphAI Therapeutics | Conditions: Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Status: COMPLETED